The Amyloidosis Channel is supported through an educational grant from Alexion Pharma GmbH.

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

ISA 2020 | Goal of therapy in AL amyloidosis: what predicts the best outcome?

Name: Goal of therapy in AL amyloidosis: what predicts the best outcome?
Uploaded: 2020-09-18T00:00:00Z
Duration: 3 min 15 s
Description: Morie Gertz, MD, MACP, Mayo Clinic, Rochester, MN, discusses the goal of therapy in immunoglobulin light chain (AL) amyloidosis and what predicts the best outcome, highlighting that free light chain ratio should not be used as a criterion or endpoint of therapy. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Morie Gertz • 18 Sep 2020

ISA 2020

Amyloidosis Rare Diseases

Morie Gertz, MD, MACP, Mayo Clinic, Rochester, MN, discusses the goal of therapy in immunoglobulin light chain (AL) amyloidosis and what predicts the best outcome, highlighting that free light chain ratio should not be used as a criterion or endpoint of therapy. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).